| Identification | Back Directory | [Name]
Methanone, [1-methyl-6-[[5-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-2-pyrazinyl]oxy]-1H-indol-2-yl][4-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]-1-piperazinyl]- | [CAS]
2591440-75-2 | [Synonyms]
Methanone, [1-methyl-6-[[5-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]-2-pyrazinyl]oxy]-1H-indol-2-yl][4-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]-1-piperazinyl]- | [Molecular Formula]
C36H29F6N7O4 | [MOL File]
2591440-75-2.mol | [Molecular Weight]
737.65 |
| Chemical Properties | Back Directory | [Boiling point ]
794.9±70.0 °C(Predicted) | [density ]
1.45±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
6.38±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
STAT3-IN-25 (compound 2p) is a potent STAT3 inhibitor with a p-trifluoroethoxy benzyl substituent. STAT3-IN-25 shows STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 22.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 32.5 nM. STAT3-IN-25 shows potent antiproliferation activities on BxPC-3 and Capan-2 cells. STAT3-IN-25 has the potential for pancreatic cancer research[1]. | [IC 50]
STAT3 | [References]
[1] Peng He, et al. Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment. J Med Chem. 2022 Nov 24;65(22):15487-15511. DOI:10.1021/acs.jmedchem.2c01554 |
|
|